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S100A7 (Psoriasin) – Mechanism of Antibacterial
Action in Wounds
Kathleen C. Lee1 and Richard L. Eckert1,2,3,4
S100A7, also called psoriasin, is a member of the S100 multigene family that is encoded in the epidermal
differentiation complex on chromosome 1q21. S100A7 is highly expressed in epidermal hyperproliferative
disease; however, its function is not well understood. These studies show high levels of monomer and
covalently crosslinked high molecular weight S100A7 in human wound exudate and granulation tissue.
Immunohistological studies suggest that this S100A7 is produced by keratinocytes surrounding the wound and
is released into the wound exudate. S100A7 is also detected in keratinocyte-conditioned cell culture medium.
Studies using recombinant S100A7 indicate that it adheres to and reduces E. coli survival. Mutation of the
conserved carboxyl-terminal EF-hand calcium-binding motif or heat denaturation slightly reduces S100A7
antibacterial activity; however, the antibacterial activity is destroyed by protease treatment. Mutation of the
zinc-binding motif, located at the C-terminus, reduces antibacterial activity; however, this reduction can be
reversed by simultaneous removal of the amino terminus. This indicates the surprising finding that the central
region of S100A7, including only amino acids 35–80, is sufficient for full antibacterial activity. These studies also
indicate that reduced S100A7 association with bacteria is associated with reduced antibacterial activity.
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INTRODUCTION
S100 proteins comprise a multigene family of low molecular
weight calcium-binding proteins that share common structur-
al motifs. These include two helix-loop-helix calcium-
binding domains (EF-hands), several a-helical domains, and
a central flexible hinge domain. Inside cells, S100 proteins
exist as antiparallel homo- and heterodimers that are held
together by non-covalent interaction (Brodersen et al., 1998;
Sastry et al., 1998; Ishikawa et al., 2000; Moroz et al., 2000).
The a-helices, which flank the calcium-binding EF-hands,
form the interface responsible for dimer formation (Drohat
et al., 1997; Drohat et al., 1998). The canonical C-terminal
EF-hand, which confers calcium sensitivity, binds calcium
with a 100-fold higher affinity than the N-terminal, non-
conventional, EF-hand (Gribenko and Makhatadze, 1998;
Zimmer et al., 2003). In response to calcium, the helices
rearrange to form a cleft in each monomer, which creates
a target protein recognition site (Brodersen et al., 1998;
Sastry et al., 1998; Donato, 1999; Rety et al., 1999; Moroz
et al., 2000; Rety et al., 2000; Donato, 2001; McClintock
and Shaw, 2003). S100 proteins are thought to participate
as regulators of a variety of intracellular processes, and
some S100 proteins also are released into the extracellular
environment (Donato, 1999; Eckert et al., 2004).
S100A7 is of particular interest in epidermal biology
because, like some other S100 proteins, it is encoded in
the epidermal differentiation complex on chromosome
1q21. This chromosomal region encodes a host of genes
(S100, involucrin, filaggrin, trichoyalin, repetin, etc.) that
are expressed in differentiating epidermis (Mischke et al.,
1996; South et al., 1999). S100A7, also called psoriasin, is
produced at low levels, by keratinocytes, in normal epidermis
(Broome et al., 2003; Glaser et al., 2005). Insides cells, it
interacts with epidermal fatty acid-binding protein (E/FABP).
E/FABP was identified in epidermis by Celis and co-workers
(Madsen et al., 1992). Although its function is not well
understood, E/FABP may be involved in fatty acid transport,
storage, and metabolism (Hertzel and Bernlohr, 2000).
Siegenthaler and co-workers confirmed that E/FABP level
is elevated in psoriasis and showed that S100A7 and E/FABP
interact in extracts of psoriatic scales (Hagens et al.,
1999a, b). S100A7 and E/FABP also interact in the cytosol
of cultured normal human keratinocytes (Ruse et al., 2003).
Moreover, differentiation of normal human keratinocytes,
by treatment with calcium/ionophore, causes movement
of S100A7 and E/FABP to cell-associated peripheral focal
adhesion-like structures that protrude from the cell surface
(Ruse et al., 2003). These findings are consistent with
immunohistological studies, which suggest that S100A7
redistributes to the cell periphery during keratinocyte
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differentiation in epidermis (Broome et al., 2003; Ruse et al.,
2003). This movement may be important, as it suggests that
S100A7, and perhaps E/FABP, may be released from
differentiated keratinocytes.
Indeed, S100A7 has been isolated from the epidermal
surface (Glaser et al., 2005). Previous studies show that
released S100A7 can function as a chemotactic agent/
cytokine (Hoffmann et al., 1994; Jinquan et al., 1996) and
as an antibacterial agent (Glaser et al., 2005; Li et al., 2005).
Regarding the latter function, Schroder and co-workers
showed that S100A7, prepared from the skin surface, can
reduce E. coli survival (Glaser et al., 2005). High antibacterial
activity was observed against E. coli strains, although S100A7
was less active against other types of bacteria (Glaser
et al., 2005). This antibacterial action against E. coli has
been confirmed using synthesized S100A7 (Li et al., 2005). In
addition, S100A7 and other S100 proteins are transglutami-
nase substrates (Robinson et al., 1997; Robinson and Eckert,
1998; Ruse et al., 2001) and several S100 proteins are
components of the keratinocyte cornified envelope (Robinson
et al., 1997). The cornified envelope is a protective structure
that is assembled adjacent the inner surface of the cell
plasma membrane during the terminal stages of keratinocyte
differentiation (Eckert et al., 1997; Nemes and Steinert,
1999). It is assembled from a pool of precursor proteins that
are covalently crosslinked to one another via the action of,
the membrane-anchored enzyme, type I transglutaminase
(Phillips et al., 1993; Steinert et al., 1996). In vitro studies
show that recombinant S100A7 is crosslinked to other
proteins by transglutaminase to form high molecular weight
heteropolymers (Robinson et al., 1997; Robinson and Eckert,
1998; Ruse et al., 2001).
Based on these observations, and the fact that S100A7 is
observed at high levels in inflammatory and hyperprolifera-
tive conditions (Madsen et al., 1991; Algermissen et al.,
1996; Broome et al., 2003), we speculated that it may also be
elevated in wounds and we further hypothesized that it may
have an antibacterial role.
Our results indicate that S100A7 is produced by keratino-
cytes surrounding the wound bed and that it accumulates
at high levels in wound exudate. Moreover, the released
S100A7 is present as monomers and covalently crosslinked
high molecular weight material. E/FABP, an S100A7 binding
partner, is also present at elevated levels in wound exudate.
Mutagenesis studies reveal that the S100A7 calcium-binding
EF-hand is not required for S100A7 antibacterial action, but
that inactivation of the zinc-binding motif reduces antibac-
terial function. Additional mutagenesis studies reveal that
the S100A7 amino terminus is not required for antibacterial
activity and that the simultaneous truncation of the carboxyl
and amino termini reveals a protein that is fully active.
Finally, we demonstrate that S100A7 interacts with bacteria
and that reduced interaction is associated with reduce
antibacterial function.
RESULTS
S100A7 has been reported to function as a chemokine in
psoriasis (Jinquan et al. , 1996) and as an antibacterial agent
on the skin surface (Glaser et al., 2005). A major goal of this
study was to examine the role of S100A7 in wounds. These
studies were prompted by the observation that S100A7
levels are elevated in human wound exudate. Partial
thickness dermatome wounds were created on buttocks
epidermis. Following the formation of granulation tissue,
wound material was harvested for assay of S100A7 level by
immunoblot. As shown in Figure 1a, S100A7 monomer
was detected at high levels in the granulation tissue (scab)
covering the wound, but not in unwounded epidermis. As
several S100 proteins are known to be present in blood and
immune cells, a key question was the site of production of the
wound-associated S100A7 (Ebihara et al., 2005). To assess
the possibility that the S100A7 present in the granulation
tissue may be derived from infiltrating blood-derived cells,
we assayed the blood of wound patients and found an
absence of S100A7 (Figure 1a). This finding is consistent with
previous reports indicating that S100A7 is not present in
blood cells. As the S100A7 was not derived from blood
cells, we hypothesized that it may be produced and released
from dermal or epidermal cells flanking the wound. To test
this, we sectioned wound tissue and assayed for the presence
of S100A7 by immunohistology. As shown in Figure 1b,
incubation with anti-S100A7 reveals the presence of S100A7
immunoreactive material throughout the epidermis surround-
ing the wound (top panel). Addition of recombinant human
S100A7 (rhS100A7) to the antibody incubation mixture
(middle panel) or omission of the secondary antibody (bottom
panel) results in a loss of signal. In contrast to the epidermis,
no staining is detected in the dermis.
Transglutaminases comprise a multigene family of en-
zymes that catalyze the formation of covalent protein–protein
crosslinks (Greenberg et al., 1991; Fesus and Piacentini,
2002; Griffin et al., 2002; Eckert et al., 2005). We had
previously shown that many S100 proteins, including
S100A7, are efficient transglutaminase substrates (Robinson
et al., 1997; Robinson and Eckert, 1998; Ruse et al., 2001),
and that crosslinking results in the formation of high
molecular weight S100 protein-positive complexes (Robinson
et al., 1997; Robinson and Eckert, 1998; Ruse et al., 2001).
Because of these properties, we assayed for formation of
covalently crosslinked S100A7 in wound exudate/granulation
tissue. As indicated in Figure 1c, rhS100A7 migrates as a
monomer. In contrast, S100A7 in normal epidermal extract is
present as high molecular weight anti-S100A7 immunoreac-
tive material (asterisk). This finding confirms our previous
report showing that low amounts of high molecular weight
covalently crosslinked S100A7 is present in normal epidermis
(Broome et al., 2003). An important finding is the presence of
increased levels of S100A7 monomer and high molecular
weight anti-S100A7 immunoreactive material in wound
exudate. This finding is consistent with the increase in
S100A7 observed in Figure 1a and b, and suggests that
S100A7 in the wound exudate functions as a transglutami-
nase substrate.
We and others have previously identified E/FABP as a
binding partner of S100A7 in epidermal extracts and in
cultured keratinocytes (Hagens et al., 1999a, b; Ruse et al.,
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2003). We therefore postulated that elevated E/FABP levels
may also be detected in extracts of wound exudate. Indeed,
as shown in Figure 1d, E/FABP levels are markedly elevated
in wound fluid. We also assessed whether S100A7 is present
in cell culture medium conditioned by keratinocytes. As
shown in Figure 1e, endogenous S100A7 is detected in
cultured keratinocytes and in keratinocyte-conditioned cell
culture medium. This finding is consistent with the idea that
keratinocytes can release S100A7.
S100A7 – an antibacterial protein
The finding that S100A7 is present in scab material suggests
that it has a role in the extracellular wound environment.
Recent studies indicate that S100A7 can inhibit bacterial
survival (Glaser et al., 2005; Li et al., 2005). We therefore
assessed whether bacterial survival can be reduced by
incubation with rhS100A7. Clinical isolates of E. coli and
Staphylococcus aureus were incubated with increasing levels
of rhS100A7 for 3 hours at 371C and then plated onto agar
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Figure 1. S100A7 expression in wounded epidermis. (a) Human blood, normal human epidermis, and human epidermal wound tissue were harvested, boiled
in Laemmli sample buffer, and electrophoresed on a 10% polyacrylamide gel. rh100A7 (1 mg) was electrophoresed in parallel. (b) Wound sections from partially
healed buttocks epidermis. Serial sections of a partially healed wound were prepared for incubation with anti-S100A7 and appropriate secondary antibody.
Parallel sections were incubated with anti-S100A7 without secondary antibody (no secondary), or in the presence of anti-S100A7þ secondary antibody and
0.5mg/ml of rhS100A7 (þ rhS100A7). (c) S100A7 is present at elevated levels in wound extracts. Extracts were prepared from punch biopsies of partially
thickness buttock wounds and from surrounding normal epidermis. Extract (30 mg protein) was electrophoresed in parallel with blood extract and rhS100A7
(0.5 mg) on a 10% polyacrylamide gel. The presence of S100A7 was measured by immunoblot. The arrow indicates the S100A7 monomer and the asterisk
indicates high molecular weight S100A7 immunoreactive bands. (d) Extracts were prepared as in panel a and then electrophoresed on a 10% acrylamide gel
before incubation with anti-E/FABP. Human blood and recombinant E/FABP (0.25 mg) was electrophoresed in parallel. This experiment was repeated three times
with identical results. (e) Keratinocytes release of S100A7 into cell culture medium. Fifty percent confluent normal human keratinocytes (35 mm dish) were
incubated in 2 ml of KSFM for 48 hours. The medium was collected, concentrated to 50 ml using a Centricon YM-3 and electrophoresed on a reducing and
denaturing 12% polyacrylamide gel. S100A7 was detected using a mouse monoclonal anti-S100A7 (Abcam, Cambridge, MA, ab13680-100) diluted 1:500.
Non-conditioned medium was processed in an identical manner.
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plates. As shown in Figure 2a, treatment with rhS100A7
markedly reduces E. coli survival. This is shown quantita-
tively in Figure 2b, which also illustrates that S100A7
treatment, at these concentrations, does not markedly impact
S. aureus survival. However, reduced S. aureus survival is
observed following treatment with higher concentrations
(250 mg/ml) of S100A7 (data not shown). Thus, the anti-
survival action of S100A7 appears to be most effective for
E. coli. Our findings are consistent with previous reports
indicating that psoriatic and atopic dermatitis-derived tissue,
which is rich in S100A7, displays enhanced resistance to
bacterial infection (Henseler and Christophers, 1995;
Algermissen et al., 1996; de Jongh et al., 2005), and the
observations by Glaser et al. (2005), which show that S100A7
treatment reduces E. coli survival.
Zinc- and calcium-binding motifs and S100A7 antibacterial
activity
S100A7, like other S100 proteins, encodes several motifs that
are thought to be important for function, including the
calcium-binding EF-hand (Zimmer et al., 1995; Schafer and
Heizmann, 1996; Heizmann and Cox, 1998) and a zinc-
binding motif (Brodersen et al., 1998, 1999). Calcium
binding to the EF-hand triggers a conformation change of
the S100A7 homodimer and exposes an internal domain that
is responsible for S100A7 interaction with target proteins
(Brodersen et al., 1998; Li et al., 2005). Binding of zinc
to the zinc-binding motif near the C-terminus (Figure 3a)
also causes a conformational change (Brodersen et al.,
1998, 1999).
It has been proposed that the antibacterial action of
S100A7 may be due to its ability to sequester zinc (Glaser
et al., 2005). To gain insight into the mechanism of action of
S100A7 as an antibacterial protein, we constructed S100A7
mutants in which the EF-hand and zinc-binding motifs
are mutated (Figure 3a), and then tested the ability of
each mutant to inhibit bacterial survival. Treatment
with 10 mg wild-type S100A7 per ml results in an 80%
reduction in E. coli survival (Figure 3b). The EF-hand mutant,
S100A7(D63,67A,K69A), is nearly as effective as wild-type
S100A7 at this concentration, suggesting that an intact EF-
hand calcium-binding domain is not required for S100A7
antibacterial activity. In contrast, removal of the zinc-binding
motif by truncation, S100A71–90 and S100A71–86, results
in a substantial reduction in antibacterial response. More-
over, this reduction in potency is also observed for
S100A7(H87,91A) in which the protein is intact except
for two key zinc coordination residues in the zinc-binding
motif. Each of these mutants reduces E. coli survival by
30–50% when applied at 10mg/ml. However, activity is
retained at higher treatment concentrations, as all of the
mutants suppress E. coli survival by 480 and 490%,
respectively, when used at concentrations of 50 and
250mg/ml, respectively. These actions of S100A7 are specific,
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Figure 2. S100A7 inhibits bacteria survival. (a) E. coli was incubated at 0, 100, and 1,000 cells/ml in 1 ml of phosphate buffer containing 1% L-Broth in the
presence or absence of 50 mg/ml S100A7 for 3 hours at 371C with shaking. The mixture was then distributed to S100 protein-free, antibiotic-free agar plates and
incubated overnight at 371C before colony counting. (b) S100A7 selectively reduces E. coli survival. E. coli or S. aureus were prepared at 1 105 cells in 1 ml in
phosphate buffer and incubated, with shaking, for 3 hours at 371C in the presence of 0, 10, and 50 mg/ml rhS100A7. The mixture was then distributed to agar
plates and colonies were counted after an overnight incubation at 371C. A substantial reduction in S. aureus survival was observed at 250 mg S100A7 per ml
(data not shown). The error bars represent mean7standard deviation. Similar results were observed in each of two experiments.
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as BSA does not reduce bacterial survival. Kanomycin, as
expected, kills the bacteria.
Figure 3b shows that mutation of the S100A7 zinc-binding
motif reduces S100A7 antibacterial activity. A previous report
indicates that pre-treatment of S100A7 with zinc sulfate
reduces S100A7 antibacterial activity (Glaser et al., 2005;
Li et al., 2005). To test this in our system, we included
10 mM zinc sulfate in incubations of E. coli treated with 10 mg
S100A7 per ml. As shown in Figure 4, the presence of zinc in
the incubation mixture did not inhibit the S100A7-associated
antibacterial action.
S100A7 is effective even after high temperature treatment
An effective antibacterial agent must withstand the high
surface temperature of sun-exposed skin. We therefore
treated S100A7 and the mutants at 1001C for 15 minutes
and then measured activity in the bacterial survival assay. As
shown in Figure 5a, heating of the various S100A7 proteins
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Figure 3. Structure of S100A7 and impact of mutation of functional domains on bacteria survival. (a) S100A7 is a one hundred one amino acid protein that
includes five major a-helical domains, two calcium EF-hand binding motifs (one dysfunctional and one functional), and a zinc-binding motif (top line).
Key amino acid residues of the EF-hand and zinc-binding motifs are indicated by boxes. The positions of the a-helices are also indicated. Amino acids that have
been changed in the mutants are underlined. Four S100A7 mutants are compared: S100A7(1–90), S100A7(1–86), and S100A7(H87,91A) encode truncation or
point mutations that destroy the zinc-binding site, and S100A7(D63,67A, K69A) encodes changes that inactivate the calcium-binding motif. (b) Impact of
S100A7 proteins on bacterial survival. E. coli bacteria (1 105) was incubated in 1 ml of phosphate buffer containing 1% L-Broth for 3 hours at 371C in the
presence of 0, 10, 50, and 250 mg/ml of the indicated S1007 mutant. Parallel cultures were treated with phosphate buffer/L-Broth, BSA, or 10 mg/ml kanomycin
for 3 hours at 371C. The cells were then plated onto S100 protein-free and antibiotic-free agar plates and incubated overnight at 371C before colony counting.
The results are presented as percent survival, and similar results were observed in each of three experiments.
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produced a modest loss of activity, which was evident when
the proteins, at 10 mg/ml, were incubated with bacteria. This
is consistent with the idea that S100 proteins are relatively
stable. The modest loss in activity may be simply due to
heat-dependent precipitation of a fraction of the protein.
All of the proteins were more effective when used at a
concentration of 250mg/ml. This stability under adverse
conditions is consistent with the observation that S100A7
antibacterial activity survives pH concentrations ranging from
5.5 to 7.4, and salt concentrations ranging from 0 and
150 mM (Glaser et al., 2005).
Our studies indicate that S100A7 levels are markedly
elevated in freshly isolated granulation tissue (see above).
However, S100A7 rapidly disappears if the scab material is
maintained at 41C overnight or is left at 251C for several
hours (data not shown). As S100A7 is stable to heating, we
hypothesized that the loss of S100A7 may be due to
proteolytic degradation. We therefore examined the impact
of treatment with proteinase K on S100A7 antibacterial
activity. S100A7 (wt) and S100A7(H87,91A), a less-active
mutant, were treated for 30 minutes with 100 ng/ml protei-
nase K before testing in the bacterial survival assay. As shown
in Figure 5b, S100A7 produces a concentration-dependent
reduction in E. coli survival, which is abrogated by pre-
treatment with proteinase K. In contrast, S100A7(H87,91A) is
not active in the presence or absence of proteinase K pre-
treatment. These findings confirm that S100A7 is susceptible
to proteinase-dependent inactivation and suggest that under
some circumstances it may be rapidly degraded in wounds.
These findings also show that S100A7 (wt) produces a 50%
reduction in bacterial survival at a concentration of 2.5 mg/ml.
S100A7 adheres to bacteria
We next performed experiments designed to study the
requirements for S100A7 action. We hypothesized that
the antisurvival action of S100A7 may require interaction
with the bacteria. To assess this, E. coli- or S. aureus-exposed
keratinocytes or bacteria-free keratinocyte cultures were
maintained in 9.6 cm2 dishes in the presence of 20 mg
S100A7 for 0.25–5 hours at 371C. The mixed bacteria–
keratinocyte cell population was washed thoroughly and
remaining adherent keratinocytes and bacteria were lysed in
sample buffer for detection of S100A7 by immunoblot. As
shown in Figure 6, S100A7 does not adhere to keratinocytes
(no bacteria, bottom panel) or to the S. aureus–keratinocyte
mixed population (middle panel). However, at 3 hours
after the start of incubation, S100A7 is observed associated
with the mixed E. coli–keratinocyte population, suggesting
that S100A7 adheres to E. coli. Thus, S100A7 appears to
adhere to E. coli, but not to S. Aureus or to keratinocytes.
We next determined whether the mutant S100A7 proteins
interact with E. coli. We first assessed this interaction in
mixed E. coli–keratinocyte cultures maintained in keratino-
cyte growth medium (in keratinocyte serum-free medium
(KSFM)) (Figure 7a). Interaction of wild-type S100A71–101,
S100A7(D63,67A,K69A), S100A7(H87,91A), and S100A71–90 is
observed in E. coli-supplemented cultures. However,
S100A71–86 does not interact as efficiently – only a small
amount is precipitated. Moreover, S100A7 (wt) does not
interact with keratinocytes in the absence of E. coli.
We next assessed whether the S100A7 proteins interact
with E. coli in the absence of keratinocytes. These
experiments were performed in phosphate buffer containing
1% L-Broth, the buffer used in the bacterial survival assays
(i.e., Figure 2). As shown in Figure 7b, all of the S100A7
forms interact with E. coli under these conditions; however,
the interaction of S100A71–86 with E. coli is again reduced.
This reduced interaction is not due to degradation during the
course of the incubation (data not shown).
The role of the S100A7 amino-terminal domain
The experiment shown in Figure 3 indicates that the carboxy-
terminal zinc-binding motif is required for optimal S100A7
antibacterial activity. To gain insight into the role of the
amino-terminal region, we constructed the mutants shown in
Figure 8a. Treatment with 10 mg wild-type S100A7 per ml
results in an 80% reduction in E. coli survival (Figure 8b). Like
the other carboxy-terminal truncation mutants described in
Figure 3, S100A71–80, which lacks most of a-helix IV, displays
reduced antibacterial activity. However, the results with the
amino-terminal truncation mutants are surprising. Both
the S100A735–101 mutant, which is intact except for the
absence of helix I and the non-functional EF-hand motif, and
the S100A735–80 mutant, which lacks both the amino- and
carboxy-terminal segments, are fully active (Figure 8b). These
findings suggest that the reduction in activity observed
in mutants lacking the carboxy-terminus can be restored
by removing the amino-terminus. In addition, these findings
suggest that the central core of the protein, amino acids
35–80, is sufficient for full function.
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Figure 4. Zinc treatment does not inhibit S100A7 action. E. coli bacteria
(1105) were resuspended in 1 ml of phosphate buffer containing 1% L-Broth
in the presence of 0 or 50 mg/ml of rhS100A7 in the presence or absence
of 10 mM zinc sulfate. After 3 hours of shaking at 371C, the cells were plated
on S100 protein-free/antibiotic-free agar plates. The plates were incubated
overnight at 371C before colony counting. The results are expressed as
percent survival. The results represent the mean7standard deviation. Similar
results were observed in each of three experiments.
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DISCUSSION
S100A7 is a member of the S100 family of proteins that
is encoded on chromosome 1q21 (Moog-Lutz et al.,
1995; Hardas et al., 1996; Kulski et al., 2003). S100A7 is
interesting, as along with S100A8 and S100A9, it is markedly
overexpressed in psoriasis, a disease associated with inflam-
mation and cell hyperproliferation (Eckert et al., 2004). These
observations suggested that S100 protein may have a role
in wound healing, a condition associated with substantial
hyperproliferation and inflammation. At least one study
indicates that S100A8 and S100A9 are produced in murine
wounds (Thorey et al., 2001). In addition, S100A7 has been
shown to have an antibacterial role on the skin surface
(Glaser et al., 2005).
Previous studies have shown that S100A7 is an efficient
transglutaminase substrate that reacts with both epidermal
transglutaminase and type II transglutaminase (Robinson and
Eckert, 1998; Ruse et al., 2001). Transglutaminases are
enzymes that catalyze the formation of covalent interprotein
e-(g-glutamyl) lysine bonds (Folk, 1980). These bonds are
formed between the e-amino group of lysine derived from
one protein and a glutamyl group of a second protein
(Folk, 1980). Type I transglutaminase is expressed in
keratinocytes and is important in the final stages of
keratinocytes differentiation during assembly of the protec-
tive barrier called the cornified envelope. Type II transglu-
taminase (tissue type) is produced by connective tissue cells
in the wound environment and in tumors and may have a role
in the remodeling events that occur during wound healing
(Griffin et al., 2002). A third transglutaminase, factor XIIIa, is
present in the blood cells that invade the wound environ-
ment (Lorand and Graham, 2003). This transglutaminase is
responsible for assembly of the fibrin clot during wound
healing (Lorand and Graham, 2003).
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Figure 5. Impact of heat and proteinase K digestion on S100A7 activity. (a) Survival of E. coli following challenge with heat-treated S100A7. E. coli (1105),
resuspended in 1 ml of phosphate buffer containing 1% L-Broth, were incubated with 0, 10, and 250 mg/ml of heat-treated S100 protein (1001C, 15 min) for
3 hours at 371C. The cells were then plated onto S100 protein-free antibiotic-free agar plates and incubated for 24 hours before colony counting. The results are
presented as percent survival. Identical results were observed in each of three experiments. (b) Proteinase K treatment destroys S100A7 antibacterial
activity. S100A71–101 (wt) or S100A7(H89,91A) were incubated in phosphate buffer containing 1% L-Broth at 1 mg/ml with 100 ng of proteinase K for 30 minutes
at 371C. The indicated amount of each S100 protein was then incubated with 1 105 bacteria for 3 hours at 371C and then plated onto S100 protein-free
antibiotic-free agar dishes. Colony number was determined after an overnight incubation at 371C. The results are expressed as percent survival, and are
representative of three separate experiments.
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In this study, high levels of S100A7 monomer were
detected in wound granulation tissue. In addition, S100A7
was detected as high molecular weight forms that were
resistant to prolonged and repeated heating in detergent and
reducing agent. Previous studies indicate that S100A7 is a
transglutaminase substrate that functions as an amine
donor, but not as a glutamyl donor. Thus, S100A7 cannot
be crosslinked to form S100A7 multimers, but can be
crosslinked to other proteins (Ruse et al., 2001). Thus, the
finding that S100A7 is present as multimers in wound
exudate indicates that it has been crosslinked to other
proteins in the wound environment. This is consistent with
in vitro studies showing that rhS100A7 is detected as high
molecular weight forms following incubation with other
proteins and transglutaminase (Ruse et al., 2001). It is likely
that the S100A7, present in the wound environment, is
crosslinked by type II transglutaminase and/or factor XIIIa to
form high molecular heteropolymers.
S100A7 is produced by wound-associated keratinocytes
Members of the S100 family are produced in a tissue-specific
manner in a wide range of tissues. Thus, the S100A7 present
in the wound environment could be produced by one or
more cell types present in the wound, including invading
immune cells, epidermal keratinocytes, or dermal fibroblasts.
Our studies show that S100A7 is not present in blood-derived
cells or in the dermis. In contrast, S100A7 expression is
increased in keratinocytes surrounding the wound. Thus, we
speculate that S100A7 is released from these cells into the
wound environment. The finding that S100A7 is expressed in
keratinocytes is consistent with previous reports (Broome
et al., 2003; Glaser et al., 2005). Moreover, S100 proteins
move to the keratinocyte cell periphery in response to
challenge with differentiating agents and may be released
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protein per plate in the presence or absence of 1105 E. coli or
S. aureus for 0–5 hours at 371C. The plates were washed three times with
phosphate-buffered saline and remaining adherent cells (keratinocytes and
bacteria) were scraped into sample buffer and sonicated. Lysate supernatant
(25–40 mg) was electrophoresed on 10% SDS-polyacrylamide gels, transferred
to nitrocellulose, and incubated with anti-S100A7 antibody (Broome et al.,
2003; Ruse et al., 2003).
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Figure 7. S100A7 mutants associate with E. coli. (a) Keratinocytes, grown in
10 ml of KSFM in 9.6 cm2 dishes until 80% confluent, were inoculated with
1 105 E. coli in the presence of 20mg of the indicated form of rhS100A7.
After 3 hours, the media was removed and the cells washed twice with
phosphate-buffered saline. The adherent cells (bacteriaþ keratinocytes)
were lysed in sample buffer by sonication and 35 mg of protein extract was
electrophoresed per lane. (b) E. coli (1 105) were suspended in 1 ml 10 mM
phosphate buffer pH7.4 containing 1% L-Broth in the presence of 20mg of
the indicated rhS100A7 protein and incubated with shaking for 3 hours
at 371C. The cells were then washed twice with phosphate buffer/L-Broth,
collected by centrifugation, and the bacterial pellet was resuspended in
sample buffer before electrophoresis. The blots were incubated with
anti-S100A7 (1:1,000) followed by goat anti-rabbit-horseradish peroxidase
secondary antibody (1:10,000). S100A7 monomer migration is indicated.
Similar results were observed in two separate experiments.
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from cultured keratinocytes (Ruse et al., 2003). Thus, S100A7
may be released from the keratinocytes into the wound fluids
via an active process, although it is also possible that S100A7
found in wound exudate is released from keratinocytes owing
to cell lysis, as cell death during tissue remodeling is
observed in wounds.
Role of the calcium- and zinc-binding motifs of S100A7
In cells, S100A7 exists as an antiparallel homodimer. In the
presence of increased intracellular calcium, the homodimer
undergoes a conformational change that results in exposure
of a hydrophobic binding domain that is thought to be
responsible for interaction of S100A7 with target proteins
(Brodersen et al., 1998, 1999). Calcium binding to the
EF-hand calcium-binding domain of S100 proteins has been
shown to be necessary for this conformational change in
some systems (Heizmann, 2002). Thus, it is interesting that
mutation of the EF-hand domain does not inhibit the ability of
S100A7 to reduce bacterial cell survival. This suggests that, at
least for the antibacterial action, calcium binding at this
location is not necessary.
In contrast, mutation of the zinc-binding motif (by targeted
mutation or truncation) resulted in a marked reduction in
S100A7 activity. For example, S100A71–80, that lacks the
zinc-binding motif, displays reduced antibacterial activity
(Figure 8). These observations are consistent with a report by
Schroder and co-workers which showed that pre-incubating
S100A7 with zinc sulfate results in a marked reduction in
S100A7 antibacterial activity (Glaser et al., 2005). Based
on this observation, it was suggested that S100A7 may reduce
bacterial survival by zinc sequestration. Although this is a
possibility, we could not detect an impact of pre-treatment
with zinc on the antibacterial activity of wild-type S100A7. It
is also important to point out that although mutation of the
zinc-binding motif reduces activity when the mutant is
applied to bacteria at 10mg/ml, the impact of the mutation is
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not observed at higher S100A7 concentrations (50–250mg/ml).
This is not an artifact due to the addition of protein, as this
effect was not observed following addition of comparable
levels of BSA. This result suggests that S100A7 may reduce
bacterial survival via multiple mechanisms, some of which
are only detected at higher S100A7 concentrations.
Removing the S100A7 amino-terminus restores activity
As noted above, removing the C-terminus of S100A7 results
in a marked reduction in antibacterial activity. We had
anticipated that removal of the N-terminus would also reduce
activity. However, we were surprised that removing the
first 34 amino acids of S100A7 (mutant S100A735–101) does
not reduce activity compared to wild-type S100A7. We were
further surprised that the loss of activity associated with
C-terminal truncation can be completely reversed by
simultaneous removal of the N-terminus. This finding
suggests that the central segment of S100A7, amino acids
35–80 (45% of the protein), is sufficient for activity. More-
over, the fact that this mutant is fully active suggests that the
zinc-binding motif is not absolutely required for activity.
Although we do not know the mechanism whereby
S100A7 reduces bacterial survival, the antibacterial activity
is associated with S100A7 interaction with the bacteria.
For example, the C-terminal mutants of S100A7, which
display reduced activity, appear to interact less efficiently
with bacteria. Based on these findings, we propose the
following model of S100A7 action in wound healing. In
normal epidermis, S100A7 is produced at low levels. During
the terminal stages of differentiation, the presence of calcium
causes S100A7 to move to the cell periphery where it serves
as a type I transglutaminase substrate (Broome et al., 2003).
Transglutaminase catalyzes the incorporation of S100A7 as a
component of the cornified envelope where it most likely
forms a cornified envelope-anchored antibacterial layer. In
wounded skin, S100A7 expression is enhanced in keratino-
cytes flanking the wound environment. The trigger for this
increased expression is not known; however, it could be a
response to inflammatory agents or to bacteria in the wound
environment (Boniface et al., 2005; Wolk et al., 2006). We
presume that the S100A7 moves to the keratinocyte cell
periphery and is then released into the wound environment.
Consistent with this possibility, we were able to show that
S100A7 is released from cultured keratinocytes. We propose
that this released S100A7 is subsequently crosslinked to other
proteins in the wound exudates via the action of type II
transglutaminase or factor XIIIa. Both enzymes are known to
be present in wound exudate. In this context, the crosslinked
S100A7 may function as a solid phase antibacterial barrier –
with the S100A7 monomers serving as a liquid phase
antibacterial barrier. In addition, we speculate that transglu-
taminase may act to crosslink S100A7 E. coli. It may be that
the antibacterial action of S100A7 is related to its specific
crosslinking to bacterial components. Finally, we should note
that E/FAPB, an intracellular protein that interacts with
S100A7 (Hagens et al., 1999a, 1999b; Ruse et al., 2003), is
also present at high levels in wound exudate. E/FABP is
thought to be involved in fatty acid transport, storage, and
metabolism (Hertzel and Bernlohr, 2000). Although it is
present at elevated levels in the wound environment, we
have not tested whether E/FABP has antibacterial activity.
MATERIALS AND METHODS
Cell culture
Primary foreskin keratinocytes were propagated and maintained in
KSFM (Gibco, Gaithersburg, MD) supplemented with pituitary
extract and epidermal growth factor as described previously
(Efimova and Eckert, 2000). These studies were conducted with
approval of the University Hospitals Human Studies Institutional
Review Board, and followed the Declaration of Helsinki Principles.
Bacterial expression plasmids
The S100A7 bacterial expression plasmid, pET28-S100A7, was used
to produce recombinant wild-type human S100A7 (Ruse et al.,
2001). Bacterial expression constructs encoding the zinc-binding
domain mutant, pET28-S100A7(H87,91A), and the calcium EF-hand
domain mutant, pET28-S100A7(D63,67A,K69A), were created using
the QuickChange mutagenesis system (Stratagene, Rockville, MD)
with pET28-S100A7 as template. The primers include 50-GCCACAG
ACTACGCCAAGCAGAGCGCTGGAGCAGCG and 50-CGCTGCT
CC AGCGCTCTGCTTGGCGTAGTCTGTGGC for S100A7(H87,91A),
and 50-GAGAAAAAGGCCAAGAATGAGGCTAAGGCGATTGATTT
TTCTGAG and 50-CTCAGAAAAATCAATCGCCT TAGCCTCATTCTT
GGCCTTTTTCTC for S100A7(D63,67A,K69A). Modified bases are
shown in underlined bold. The upstream primer 50-GGCATATGAGC
AACACTCAAGCTGAG and downstream primers 50-AATGAATTCA
GCTCTGCTTGTGG and 50-CATGAATTCAGTAGTCTGTGGCTA
TGTTGTC were used to produce S100A71–90 and S100A71–86,
respectively, using pET28-S100A7 as template. To produce
S100A735–80, the upstream primer 5
0-CTGCTGCATATGATGAAGG
AGAACTTCC and the downstream primer 50-CATGAATTCATCCC
AGCAAGGACAGAAAC were used. The upstream primer 50-
GGCATATGAGCAACACTCAAGCTGAG and downstream primer
50-CATGAATTCATCCCAGCAAGGACAGAAAC were used to create
S100A71–80. The upstream primer 5
0-CTGCTGCATATGATGAAGG
AGAACTTCC and the downstream primer 50-TAGGATCCTGGG
TCTCTGGAGGCCCATTG were used to create S100A735–101. The
PCR products were NdeI/BamHI restricted and cloned into pET28.
All recombinant S100A7 proteins contain a polyhistidine tract at the
amino terminus, which serves as an affinity chromatography
purification anchor.
Protein expression and purification
rhS100A7 proteins were produced in E. coli BL21-DE3 using 1 mM
isopropyl-thiogalactopyranoside to induce expression. Frozen bac-
terial pellets were thawed and resuspended in lysis buffer containing
10 mM Tris, pH 7.9, 200 mM NaCl, 0.5 mM EDTA, 10% glycerol,
0.1% Igepal, 10 mM imidazol, and protease inhibitors (CalBiochem,
San Diego, CA). The cells were then sonicated and centrifuged,
and the supernatant was incubated with nickel-nitrilotriacetic
acid resin at 41C. The resin was then washed with 10 mM Tris,
pH 7.9 buffer, containing 0.2% Igepal, 300 mM NaCl, 10% glycerol,
15 mM imidazol, protease inhibitors, and 1 mM phenylmethylsulfonyl
fluoride. Recombinant proteins were eluted using 10 mM Tris buffer,
pH 7.9, containing 0.1% Igepal, 200 mM NaCl, 10% glycerol,
250 mM imidazol, and protease inhibitors. The eluded proteins were
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dialyzed into 10 mM Tris, pH 7.9 buffer containing 200 mM NaCl,
10% glycerol, 1 mM EDTA, 1 mM EGTA, and 1 mM phenylmethylsul-
fonyl fluoride followed by dialysis in 10 mM sodium phosphate
buffer, pH 7.4. Protein aliquots were stored frozen at 801C.
Immunoblot analysis
Normal epidermis, scab granular material, and blood were collected
and processed immediately by addition of 1 Laemmli buffer,
followed by sonication. Protein concentration was quantified by
Bradford Assay (BioRad, Hercules, CA). Extract (25mg) was electro-
phoresed on 10% SDS-polyacrylamide gels and transferred
to nitrocellulose membrane. The membranes were incubated in
blocking buffer (5% milk in Tris-buffered saline with Tween) at room
temperature for 60 minutes and then incubated with anti-
bodies specific for human S100A7 (diluted 1:1,000) (Ruse et al.,
2001; Broome et al., 2003) or E/FABP (1:500) (Cell Sciences Inc.,
Boston, MA). The blots were washed and incubated with anti-rabbit-
horseradish peroxidase (Amersham Pharmacia, Piscataway, NJ,
1:10,000). Primary antibody binding was visualized using chemi-
luminescence detection reagents.
Bacterial survival assay
The antimicrobial activity of purified wild-type and mutant S100A7
proteins was estimated using a microdilution assay system (Glaser
et al., 2005). Clinical isolates of E. coli or S. aureus were used for all
experiments. Bacteria were streaked onto antibiotic-free agar plates.
A single colony was used to grow a small overnight culture in
L-Broth which was then diluted in 10 mM sodium phosphate
buffer containing 1% L-Broth. rhS100A7 protein was added and
the mixture was incubated for 3 hours at 371C, spread on S100
protein-free and antibiotic-free agar plates and incubated at 371C
overnight followed by colony counting. Where indicated, bacteria
were incubated with 10 mg/ml kanamycin, BSA, rhS100A7 protein
boiled 15 minutes at 1001C, or proteinase K-digested rhS100A7
protein. For proteinase K digestion, rhS100A7 proteins were
included with 100 ng/ml proteinase K for 30 minutes at 371C before
incubation with bacteria.
S100A7–bacteria association assay
Fifty to seventy-five percent confluent cultures of primary human
epidermal foreskin keratinocytes, maintained in 10 ml of KSFM in
9.6 cm2 plates, were incubated with 10–50 mg rhS100A7 protein per
dish in the presence or absence of 1 105 E. coli or S. aureus for
3 hours at 371C. After incubation, cells (keratinocytes and bacteria)
were rinsed three times with sterile phosphate-buffered saline.
Adherent keratinocytes and bacteria were collected by scraping and
lysed by sonication in Laemmli sample buffer. The cell lysate
was centrifuged at 15,000 g for 10 minutes, and the supernatant
was collected. Supernatant (25–40 mg) was electrophoresed on
10% SDS-polyacrylamide gels, transferred to nitrocellulose, and
incubated with anti-S100A7 antibody (1:1,000) (Broome et al., 2003;
Ruse et al., 2003) followed by anti-rabbit-horseradish peroxidase
(1:10,000). Bands were then visualized using the enhanced-
chemiluminescence reagent (Amersham, Piscataway, NJ).
For rhS100A7 protein association with bacteria in the absence of
keratinocytes, bacteria (E. coli or S. aureus) were diluted to
1 105 cells/ml in 10 mM sodium phosphate buffer, pH 7.4,
containing 1% L-Broth. rhS100A7 protein (10–50 mg/ml) or buffer
was added to the diluted bacteria and then incubated at 371C for
3 hours with shaking. Bacteria were then collected by centrifugation,
rinsed gently two times with 10 mM sodium phosphate buffer, pH
7.4, and resuspended in Laemmli buffer. The resuspended cells
were sonicated briefly and the supernatant was run on a 10%
polyacrylamide gel. After transfer, the membranes were blocked and
probed with anti-S100A7 antibody (1:1,000) followed by anti-rabbit-
horseradish peroxidase antibody (1:10,000).
Immunohistology
Human wound epidermis was obtained through the Translational
Studies Core of the Skin Diseases Research Center of Northeast
Ohio. Samples were fixed in 10% formalin (Surgipath, Richmond,
IL), paraffin embedded, and sectioned onto microscope slides.
Deparaffinized and rehydrated sections were rinsed in phosphate-
buffered saline and blocked for 60 minutes at 251C in phosphate-
buffered saline containing 1.5% goat serum (Vector Laboratories,
Burlingame, MA). Sections were incubated overnight at 251C
with rabbit anti-hS100A7 (1:250) with or without pre-incubation
with rhS100A7 (3 mg rhS100A7/1 mg anti-S100A7 antibody). The
sections were rinsed with phosphate-buffered saline and incubated
for 1 hour at 51C with biotin-labeled secondary antibody (goat
anti-rabbit IgG, Vector Laboratories, Burlingame, MA). After wash-
ing, the sections were incubated with avidin–biotin–peroxidase
complex (Vectastain kit, Vector Laboratories, Burlingame, MA)
for 30 minutes, rinsed, stained with 3,30-diaminobenzidine
(SK4100, Vector Laboratories, Burlingame, MA), and counterstained
with hematoxylin and eosin.
Analysis of human epidermal wounds
Tissue harvested from epidermal wounds was obtained though the
Translational Studies Core of the Skin Diseases Research Center of
Northeast Ohio. An abrasion wound was produced on the buttocks
of a human volunteer using a sterile scalpel. At 72 hours post-injury,
8 mm punch biopsies were taken from the wound and from adjacent
intact tissue and processed immediately for immunoblot and
immunohistochemistry. These studies were approved by the Institu-
tional Review Board for human studies.
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